Related Experiment Videos
[Secondary prevention of ischemic heart disease after coronary revascularization]
E Delacrétaz1, J Ruiz, P G Michalopoulos
1Inselspital, Bern.
Insights
One year after coronary artery revascularization, many patients with hyperlipidemia were not receiving adequate lipid-lowering therapy, indicating poor compliance with secondary prevention guidelines for coronary heart disease.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Context:
- Secondary prevention of coronary heart disease (CHD) is crucial after revascularization procedures.
- Hyperlipidemia management is a key component of CHD secondary prevention.
- Assessing treatment compliance one year post-revascularization provides insight into long-term patient management.
Purpose:
- To evaluate compliance with secondary prevention policies for CHD.
- To assess the management of hyperlipidemia one year after coronary artery revascularization.
- To determine treatment patterns for hypercholesterolemia and their impact on lipid levels.
Summary:
- A study of 186 patients one year after coronary artery bypass grafting or percutaneous transluminal coronary angioplasty found low rates of lipid-lowering therapy (30-38%) among those with elevated cholesterol.
- The majority of patients (97%) received antiplatelet or coumadine therapy.
- Participation in a rehabilitation program improved smoking cessation but not hyperlipidemia treatment.
Impact:
- Findings highlight inadequate adherence to hyperlipidemia treatment guidelines in CHD patients post-revascularization.
- Results underscore the need for improved strategies to manage lipid disorders in this high-risk population.
- The study suggests a gap in care regarding comprehensive secondary prevention for coronary heart disease.
Abstract:
This study was aimed to assess the compliance with policies for secondary prevention of coronary heart disease (CHD) one year after coronary artery revascularization with special attention to the management of hyperlipidemia. One year after coronary revascularization during the year 1994, patients were contacted by letter to determine the modification of their risk factors, the treatment patterns for hypercholesterolemia and to have their plasma lipid level and blood pressure measured. Of the 245 consecutive patients contacted (110 after coronary artery bypass grafting, and 135 after percutaneous transluminal coronary angioplasty), 186 (76%) provided the information required for further analysis. Excluding the patients older than 65 years, only 29 out of 97 patients (30%) with a total cholesterol of more than 5.2 mmol/l, and only 20 out of 52 patients (38%) with a total cholesterol of more than 6.2 mmol/l were receiving lipid lowering therapy 1 year after coronary artery revascularization. In contrast, 97% (n = 180) of the entire population studied were taking antiplatelet drugs and/or coumadine. Participation in an in-house rehabilitation program yielded a positive influence on smoking, but not on treatment of hypercholesterolemia. In conclusion, only a small proportion of patients with documented CHD and hypercholesterolemia were being treated for their lipid disorder 1 year after coronary artery revascularization. In contrast, the great majority of patients received antiplatelet and/or coumadine therapy: These results indicate that the compliance with published treatment guidelines for hyperlipidemia in patients with CHD is still highly inadequate, irrespective of the participation in a rehabilitation program.